Pembrolizumab (Immunotherapy)
Treatment for Lip and oral cavity cancer
Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Effectiveness
75%
Safety Score
60%
Clinical Trials
2
Participants
40K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
Weeks to months
Treatment Duration
Every 3 or 6 weeks, until progression or toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$15,000
Side Effect Mgmt:$8,000
Total Annual:$203,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$350,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$580,000
Cost per Remission
$2,537,500
Comparison vs Chemotherapy (e.g., EXTREME regimen)
Cost Difference
+$170,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (Immunotherapy) Outcomes
for Lip and oral cavity cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+35%
Remission Rate
+8%
Common Side Effects
Fatigue
+25%
Rash
+15%
Pruritus
+12%
Hypothyroidism
+8%
Immune-related colitis
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Pembrolizumab (Immunotherapy) in Lip and oral cavity cancer
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228RECRUITINGPHASE1, PHASE2
242 participants
INTERVENTIONAL
Santa Rosa, United States +14 more
Started: Jun 8, 2018
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258ACTIVE NOT RECRUITINGPHASE2
52 participants
INTERVENTIONAL
Duarte, United States +19 more
Started: Jul 26, 2022
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05721755ACTIVE NOT RECRUITINGPHASE3
290 participants
INTERVENTIONAL
Tampa, United States +50 more
Started: Jun 8, 2023
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT07552558NOT YET RECRUITINGPHASE1, PHASE2
45 participants
INTERVENTIONAL
St Louis, United States
Started: Jun 30, 2026